Skip to main content
Propanc Biopharma, Inc. logo

Propanc Biopharma, Inc. — Investor Relations & Filings

Ticker · PPCB ISIN · US74346N4043 LEI · 549300Q3HY827FNV8Y56 US Professional, scientific and technical activities
Filings indexed 411 across all filing types
Latest filing 2026-04-10 Registration Form
Country US United States of America
Listing US PPCB

About Propanc Biopharma, Inc.

https://www.propanc.com/

Propanc Biopharma, Inc. is a clinical-stage company developing cancer treatments focused on preventing tumor recurrence and metastasis. Its lead candidate, PRP, is a pancreatic proenzyme formulation designed to target and eradicate cancer stem cells. The therapeutic approach aims to suppress tumor progression by controlling cancer cell migration, inhibiting the formation of tumor blood vessels, and inducing cell death. The company's primary focus is on developing long-term therapies for patients with solid tumors, such as pancreatic cancer.

Recent filings

Filing Released Lang Actions
S-1 - Propanc Biopharma, Inc. (0001517681) (Filer)
Registration Form
2026-04-10 English
PRE 14A - Propanc Biopharma, Inc. (0001517681) (Filer)
Regulatory Filings
2026-03-19 English
8-K - PROPANC BIOPHARMA, INC. (0001517681) (Filer)
Regulatory Filings
2026-02-26 English
10-Q Filing
Interim / Quarterly Report Q2 2026
2026-02-17 English
S-1 Filing
Registration Form
2026-02-02 English
8-K
Regulatory Filings
2026-01-07 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.